Beckman launches fully quantitative COVID-19 IgG test

Create PDF

May 20, 2021—Beckman Coulter launched its Access SARS-CoV-2 IgG (1st IS), a fully quantitative lab-based immunoglobulin G serology test that measures the quantity of antibodies against the virus that causes COVID-19. The assay is traceable to the First WHO International Standard for anti-SARS-CoV-2, 20/136, and reports results aligned with BAU/mL established by the World Health Organization.

In a clinical study, the Access SARS-CoV-2 IgG (1st IS) test showed a clinical performance of 100 percent sensitivity and 99.8 percent specificity (exclusion of false-negatives and false-positives, respectively) in patients tested 15 days or more post-symptom onset.